
|Articles|November 15, 2016
- Pharmaceutical Technology-11-15-2016
- Volume 2016 eBook
- Issue 3
Extending QMS to Contract Partners
Author(s)Agnes Shanley
Advances in cloud-based IT and user interfaces make it easier to collaborate, but a strong foundation, based on knowledge of data and risk management principles, is needed first.
Advertisement
This interview with Patricia Santos Serrao, director of clinical and regulatory solutions, and Matt Lowe, executive vice president of Master Control, discusses the roots of problems with corrective and preventive action (CAPA) and documentation of standard operating procedures (SOPS), and how Quality Management Systems (QMS) software is being improved to address them, and to make it easier to collaborate and communicate with contract partners.
Articles in this issue
about 10 years ago
Investigation Effectiveness Drives Human Performance Excellenceabout 10 years ago
Is Global Regulatory Gridlock Slowing Modernization?about 10 years ago
Paperless Batch Records for the Massesabout 10 years ago
Ensuring Quality in Pharmaceutical Raw Materialsabout 10 years ago
Microbiological Testing: Time is of the EssenceAdvertisement
Related to this article

How confident is the bio/pharma workforce heading into 2027? PharmTech wants to find out, and we need your input.

Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.

The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.

EU GMP Annex 22: AI Pulse Check panelists say most manufacturers aren’t ready, static AI models likely stay central, and local AI deployment grows.

Nate Edwards of Arya Consulting, Elisabeth Gardiner of Tevard Biosciences, and Donny Xu of the RTW Institute discuss global competition for rare disease therapies.

Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Neladalkib Accelerated Approval: What ALK Drug Developers Should Know
2
Salalah Free Zone: A Gateway for Pharmaceutical and MedTech Investment
3
CPHI Awards Winner for Manufacturing Excellence: Anemocyte and mRNA Synthesis
4
Giredestrant Takes ESR1 Breast Cancer Treatment Into Oral Solid Doses
5


